Patents by Inventor Joshua M. Hare

Joshua M. Hare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250073277
    Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
    Type: Application
    Filed: November 18, 2024
    Publication date: March 6, 2025
    Applicant: University of Miami
    Inventors: Joshua M. HARE, Konstantinos CHATZISTERGOS
  • Patent number: 12168028
    Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 17, 2024
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Joshua M. Hare, Konstantinos Chatzistergos
  • Publication number: 20240350551
    Abstract: Compositions and methods are disclosed herein for the treatment of aging frailty with bone marrow derived mesenchymal stem cells. The methods of treatment involve the administration of a composition of bone marrow derived mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved physical activity.
    Type: Application
    Filed: September 9, 2022
    Publication date: October 24, 2024
    Applicant: Longeveron Inc.
    Inventors: Joshua M. HARE, Anthony A. OLIVA, Ben HITCHINSON
  • Publication number: 20240350549
    Abstract: The present disclosure provides methods for treating hypoplastic left heart syndrome in patients in need thereof, the methods involving the administration of a therapeutically effective amount of mesenchymal stem cells. The methods may further involve measuring various biomarkers related to cardiac health and function after administration of the mesenchymal stem cells to determine both the efficacy of the treatment and whether more mesenchymal stem cells need to be administered for a therapeutic effect to occur.
    Type: Application
    Filed: July 26, 2022
    Publication date: October 24, 2024
    Applicant: Longeveron Inc.
    Inventors: Joshua M. HARE, Sunjay KAUSHAL
  • Publication number: 20240252627
    Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 1, 2024
    Applicant: Longeveron Inc.
    Inventors: Joshua M. HARE, Ana Marie LANDIN
  • Patent number: 11975068
    Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 7, 2024
    Assignee: LONGEVERON, INC.
    Inventors: Joshua M. Hare, Ana Marie Landin
  • Publication number: 20230310509
    Abstract: Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 5, 2023
    Applicant: Longeveron, Inc.
    Inventors: Joshua M. HARE, Anthony A. OLIVA
  • Publication number: 20230071551
    Abstract: Methods for the isolation of CD271+ stem cell populations are important in the prevention or treatment of cardio-vascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.
    Type: Application
    Filed: July 8, 2022
    Publication date: March 9, 2023
    Inventors: Joshua M. Hare, Ian K. McNiece
  • Publication number: 20220002804
    Abstract: The present disclosure is directed to methods for determining responsiveness to cell therapy in a subject suffering from a cardiovascular disorder (e.g., cardiomyopathy) and methods of treating subjects suffering from a cardiovascular disorder.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Inventor: Joshua M. Hare
  • Publication number: 20210302437
    Abstract: Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.
    Type: Application
    Filed: November 9, 2020
    Publication date: September 30, 2021
    Inventors: Joshua M. HARE, Bettina HEIDECKER
  • Publication number: 20210260133
    Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.
    Type: Application
    Filed: September 28, 2020
    Publication date: August 26, 2021
    Inventors: Konstantinos E. CHATZISTERGOS, Joshua M. HARE
  • Patent number: 10786536
    Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: September 29, 2020
    Assignee: VESTION, INC.
    Inventors: Konstantinos E. Chatzistergos, Joshua M. Hare
  • Publication number: 20200246389
    Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 6, 2020
    Inventors: Joshua M. Hare, Konstantinos Chatzistergos
  • Publication number: 20200129558
    Abstract: Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.
    Type: Application
    Filed: June 15, 2018
    Publication date: April 30, 2020
    Applicant: LONGEVERON LLC
    Inventors: Joshua M. Hare, Darcy L. DiFede
  • Publication number: 20200115755
    Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 16, 2020
    Inventors: Joshua M. HARE, Bettina HEIDECKER
  • Patent number: 10555987
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 11, 2020
    Assignees: UNIVERSITY OF MIAMI, U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew Schally, Joshua M. Hare, Norman Block, Samirah Gomes, Rosemeire M. Kanashiro-Takeuchi
  • Publication number: 20190290698
    Abstract: The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 26, 2019
    Applicant: Longeveron LLC
    Inventors: Joshua M. Hare, Ana Marie Landin
  • Publication number: 20190038742
    Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Applicant: Longeveron LLC
    Inventors: Joshua M. HARE, Ana Marie LANDIN
  • Patent number: 10131948
    Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 20, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Joshua M. Hare, Bettina Heidecker
  • Publication number: 20180250358
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Application
    Filed: November 21, 2017
    Publication date: September 6, 2018
    Inventors: Andrew Schally, Joshua M. Hare, Norman Block, Samirah Gomes, Rosemeire M. Kanashiro-Takeuchi